Photomicrograph of a Nerium oleander leaf.
Nerium oleander cultivation.
Robert A. Newman, Ph.D., Chief Science Officer, PBI, Inc.
Photomicrograph of human nerve cells.

Phoenix Biotechnology, Inc. (PBI)'s Focus

Phoenix Biotechnology, Inc., located in San Antonio, TX has been exploring the health-related benefits of a novel extract of Nerium oleander for the past 20 years. The company has developed a supercritical CO2 extraction of Nerium oleander into a new botanical drug – PBI-05204.

PBI-05204 is a ‘botanical drug’ that has been through initial FDA review and approved for the Phase I and Phase II clinical trials which were conducted in the United States. These trials have shown that this oral (capsule) formulation is safe for administration to patients without undue toxicity.

A distinction of PBI-05204 is that research has consistently proven that this drug crosses the blood brain barrier which opens up several potential applications. Extensive research has been done in the following areas: Antiviral, Cancer, and Neurodegenerative Diseases.


July, 2020
Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by Oleandrin” – was produced following research conducted this spring and summer by scientists at the University of Texas Medical Branch in Galveston, Texas, the University of Texas MD Anderson Cancer Center and Phoenix Biotechnology, Inc. Any product(s) resulting from this research will not be available until approved by the US Food & Drug Administration.


April, 2020
Dr. John Dye, chief of viral immunology at the USAMRIID lab at Fort Detrick, confirmed that his team began testing the extract known as oleandrin a few years ago and found it was effective in fighting the Ebola and Marburg viruses. The Army lab is now ramping up a rapid plan to test oleandrin against COVID-19.


February, 2020
PBI sponsored research at the University of Texas at San Antonio has demonstrated that PBI-05204 leads to a marked reduction in neuroinflammtion in brain microglial cells in vitro. Importantly, when fed to mice orally the PBI drug also produces a significant reduction in accumulation of beta-amyloid plaques within the brains of specifically bred transgenic mice that develop Alzheimer’s-like disease. Taken together ,these recent findings suggest that further exploration of the utility of PBI-05204 for neurodegenerative diseases like Alzheimer's is warranted.